Package Thrombophilia (Leiden mutation, mutation in FVIII gene, C677T mutation in MTHFR gene)
Material: Blood
Price of the study: 400 PLN
Waiting time: result after 21 working days
Booking:
Price of the study: 400 PLN
Waiting time: result after 21 working days
Booking:
- Check, the hours of operation of the collection center and where booking an appointment is required.
Preparation for the study
General
- The test material is blood.
- The patient does not need to be fasting.About 30 minutes before the test, it is advisable to drink a glass of water or bitter(unsweetened) tea.
Important
Samples brought from outside are not accepted for testing.
Description
The most common manifestation of congenital thrombophilia is deep vein thrombosis of the lower extremities. Thrombophilia is considered one of the main risk factors for venous thromboembolism. It is detected in 41% of patients with deep vein thrombosis. The risk of thrombosis is highest in patients with antithrombin deficiency.
Thrombotic changes conditioned by congenital or acquired thrombophilia can cause recurrent miscarriages, intrauterine fetal death, premature separation of the placenta and preeclampsia. Nowadays, genetic diagnosis for thrombophilia is already recommended in cases of two or more miscarriages in one partnership.
It is estimated that the Leiden mutation in factor V is responsible for about 20% of obstetric complications, while the mutation in factor II affects about 10% of cases. The risk of miscarriage increases when polymorphisms in the MTHFR gene are additionally present. In women who have experienced habitual miscarriages, factor V Leiden analysis, prothrombin gene mutation, and analysis of selected mutations in the MTHFR gene should be performed.
The thrombophilia package detects factor V Leiden mutations, mutations in the factor II gene, and the C677T mutation in the MTHFR gene.
Thrombotic changes conditioned by congenital or acquired thrombophilia can cause recurrent miscarriages, intrauterine fetal death, premature separation of the placenta and preeclampsia. Nowadays, genetic diagnosis for thrombophilia is already recommended in cases of two or more miscarriages in one partnership.
It is estimated that the Leiden mutation in factor V is responsible for about 20% of obstetric complications, while the mutation in factor II affects about 10% of cases. The risk of miscarriage increases when polymorphisms in the MTHFR gene are additionally present. In women who have experienced habitual miscarriages, factor V Leiden analysis, prothrombin gene mutation, and analysis of selected mutations in the MTHFR gene should be performed.
The thrombophilia package detects factor V Leiden mutations, mutations in the factor II gene, and the C677T mutation in the MTHFR gene.
Development and preparation of material (applies to contractors only)
983
